Healthy Volunteers
Conditions
Brief summary
This is a phase 1 open-label study
Detailed description
This is a phase 1 open-label study. The objective of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral administered SHR2285 in healthy subjects
Interventions
DRUGSHR2285
SHR2285 is a selective inhibition of human FXIa small molecule compound.
Sponsors
Atridia Pty Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Three different cohorts can enroll healthy Caucasian participants; males and females in each cohort separately.
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Ability to understand the trial procedures and possible adverse events, volunteers to participate in the trial, and provides written informed consent. * Be able to comply with all the requirements and able to complete the study. * Male or female aged between 18 years and 55 years (inclusive) at the date of signed consent form. * No clinically significant abnormalities in medical history, general physical examination, vital signs, and laboratory tests. * Men and women of childbearing potential (WOCBP) must agree to take effective contraceptive methods and have no plan to have a child from signing the consent form to 16 weeks after IP administration.
Exclusion criteria
* Receipt of any other investigational drugs or medical devices within 3 months prior to screening (according to the date of signed consent form). * History of illicit or prescription drug abuse or addiction within one year of screening, or positive urine drug screen at screening and Day-1. The urine drug screen may be repeated at the discretion of the investigator and the reason for repeat needs to be documented clearly (e.g., suspicion of false positive due to diet). * Receipt of any other investigational drugs or medical devices within 3 months prior to screening (from the date of signed consent form).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | Start of Treatment to end of study (approximately 7 days) | Incidence and severity of adverse events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics-t1/2 | Up to 3 days | Terminal elimination half-life of SHR2285 and its metabolite SHR164471 |
| Coagulation factor XI (FXI) activity | Up to 3 days | Coagulation factor XI (FXI) activity |
| Pharmacokinetics-AUC0-last | Start of Treatment to outpatient (approximately 3 days) | Area under the concentration-time curve from time 0 to last time point after SHR2285 administration |
| Pharmacokinetics-AUC0-inf | Start of Treatment to outpatient (approximately 3 days) | Area under the concentration-time curve from time 0 to infinity after SHR2285 administration |
| Pharmacokinetics-Tmax | Up to 3 days | Time to Cmax of SHR2285 and its metabolite SHR164471 |
| Pharmacokinetics-Cmax | Up to 3 days | Maximum observed concentration of SHR2285 and its metabolite SHR164471 |
| Pharmacokinetics-CL/F | Up to 3 days | Apparent clearance of SHR2285 and its metabolite SHR164471 |
| Pharmacokinetics-Vz/F | Up to 3 days | Apparent volume of distribution during terminal phase of SHR2285 and its metabolite SHR164471 |
| Activated partial thromboplastin time | Up to 3 days | Activated partial thromboplastin time |
| Fold change of activated partial thromboplastin time from baseline | Up to 3 days | Fold change of activated partial thromboplastin time from baseline |
| Prothrombin time | Up to 3 days | Prothrombin time |
| Fold change of prothrombin time from baseline | Up to 3 days | Fold change of prothrombin time from baseline |
| International normalized ratio | Up to 3 days | International normalized ratio |
| Fold change of international normalized ratio from baseline | Up to 3 days | Fold change of international normalized ratio from baseline |
| Percentage change of coagulation factor XI (FXI) activity thromboplastin time (APTT) and fold change from baseline | Up to 3 days | Percentage change of coagulation factor XI (FXI) activity |
Countries
Australia
Outcome results
None listed